Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Runda Medical Technology Co., Ltd.
  6. News
  7. Summary
    603108   CNE100002318

SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.

(603108)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-29
10.34 CNY   -.--%
08/26Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
05/29Zero-COVID, big money: China's anti-virus spending boosts medical, tech, construction
RE
05/11Accuracy of Runda Medical’s COVID-19 Testing Questioned by Shanghai Bourse
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Zero-COVID, big money: China's anti-virus spending boosts medical, tech, construction

05/29/2022 | 11:14pm EDT
FILE PHOTO: COVID-19 testing in Shanghai

BEIJING, May 30 (Reuters) - China's 'zero-COVID' policy of constantly monitoring, testing and isolating its citizens to prevent the spread of the coronavirus has battered much of the country's economy, but it has created bubbles of growth in the medical, technology and construction sectors.

The Chinese government, alone among major countries in vowing to eradicate the coronavirus within its borders, is on track to spend more than $52 billion (350 billion yuan) this year on testing, new medical facilities, monitoring equipment and other anti-COVID measures, which will benefit as many as 3,000 companies, according to analysts.

"In China, the companies that provide testing services and other related industries are making big money because of the government's focus on a containment-based approach in fighting COVID," said Yanzhong Huang, a global health specialist at the Council on Foreign Relations (CFR), a U.S. think tank.

China aims to have COVID testing facilities within 15-minutes' walk of everyone in its big cities and continues to impose mass testing at the slightest sign of an outbreak. Hong Kong-based Pacific Securities estimates this has created a market worth more than $15 billion a year for test makers and providers.

The government is footing the bill for the vast majority of this, either by buying test kits or paying companies to do tests. Although prices of tests have dropped since the outbreak of the coronavirus in early 2020 – to as little as 50 cents per test - this continuing demand has helped a number of companies.

First-quarter profit more than doubled for Hangzhou-based Dian Diagnostics Group Co Ltd, one of China's biggest medical test makers. Its revenue jumped more than 60% to $690 million, just less than half of which was for its COVID testing services, almost entirely paid for by the government.

Rival Adicon Holdings Ltd, which received about $300 million of mostly government money for its COVID tests over 2020 and 2021, according to the company's financial statements, has applied for an initial public offering on the Hong Kong stock exchange.

Shanghai Runda Medical Technology Co Ltd said it was processing up to 400,000 COVID tests per day in April, during the almost two-month-long lockdown of Shanghai, generating more than $30 million a month, according to an article by the state-run Securities Times.

China defends its 'zero-COVID' policy as crucial to saving lives and preventing its healthcare system from being overrun. It shows little sign of pulling back even as the economic toll mounts.

The latest indicators show the country's economy has weakened sharply since March, as employment, consumer spending, exports and home sales have been hit by stringent lockdown measures that clogged highways and ports, stranded workers and shut factories.

Many private-sector economists expect the economy to shrink in the April to June quarter from a year earlier, compared with the first quarter's 4.8% growth. The blue-chip CSI 300 Index is down 19% this year.

Investors are uncertain how long the boom will last for companies like Dian, Adicon and Shanghai Runda, whose fortunes are closely tied to government spending. Analysts, on average, expect Dian's revenue to dip slightly next year, while they see Shanghai Runda's continuing to grow. Stocks of both are down from the start of this year.

"The development of the epidemic is uncertain due to the large number of mutated strains of the new coronavirus and the complexity of infectiousness," said a recent research note by Shenzhen-based Essence Securities. "If the spread of the epidemic is well controlled and the epidemic prevention policy is adjusted, it may have a negative impact on the market demand for COVID nucleic acid testing."

Huang at the CFR said that China's massive program of lockdowns, tracing and isolating could prevent a worst-case scenario but was not a permanent solution. "Epidemiologically and economically, it is unsustainable," he said.

Dian Diagnostics, Adicon and Shanghai Runda did not respond to requests for comment. Health authorities in Beijing and Shanghai did not respond to requests for comment.

MASS SURVEILLANCE, QUICK BUILDINGS

Dozens of surveillance and thermal imaging camera manufacturers, such as Wuhan Guide Infrared Co Ltd and Hangzhou Hikvision Digital Technology Co Ltd, have benefited from the Chinese government's demand for gadgets that can help it keep track of the COVID status of its 1.4 billion citizens.

Wuhan Guide, one of the world's leading manufacturers of thermal imaging equipment, doubled its revenue in 2020 as it worked overtime to supply fever-detecting cameras across China and overseas. Growth flattened out last year, but analysts expect it to pick up again this year and next. The company did not respond to a request for comment.

Disease has been the mother of invention. Since March, Chinese companies and research institutes have filed at least 50 COVID-related patents, according to a Reuters review of international and domestic databases. The inventions are mostly related to adapting existing surveillance cameras and platforms in order to track close contacts and identify potential positive cases.

The urgent need for hundreds of new hospitals, to take the strain off China's already-stretched medical infrastructure, has created a boom for some construction companies.

Beijing-based China Railway Group Ltd, a conglomerate spanning construction, manufacturing and real estate, has built makeshift hospitals all over China this year, and has been particularly active in areas hit hard by COVID such as Shanghai and the northeastern city of Changchun. Its profit has grown steadily over the past two years, at least partly helped by COVID-related projects, and analysts expect that to continue over the next few years. Its stock hit a three-year high in May. China Railway Group did not respond to a request for comment.

One analyst has estimated that about 300 makeshift hospitals were built around China during a 35-day span between March and April, as infections surged, at a cost of more than $4 billion.

One third of those were built in and around Shanghai. There is no sign of waning demand from the government. On May 15, China's National Health Commission head Ma Xiaowei called for the construction of what he called "permanent makeshift hospitals" in leading Chinese Communist Party publication Qiushi, suggesting that there will be a long-term need for such buildings.

A Reuters review of tenders for such projects suggest the government will spend about $15 billion this year on new hospitals. (Reporting by Eduardo Baptista in Beijing Editing by Bill Rigby)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACCENT GROUP LIMITED -2.85% 1.365 Delayed Quote.-42.65%
CHINA RAILWAY CONSTRUCTION CORPORATION LIMITED 0.58% 6.97 End-of-day quote.-10.64%
CHINA RAILWAY GROUP LIMITED 0.19% 5.23 End-of-day quote.-9.67%
DIAN DIAGNOSTICS GROUP CO.,LTD. -2.39% 29.02 End-of-day quote.-13.55%
HANGZHOU HIKVISION DIGITAL TECHNOLOGY CO., LTD. 0.03% 30.42 End-of-day quote.-41.86%
MEDICAL FACILITIES CORPORATION -1.39% 10.64 Delayed Quote.13.80%
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD. 0.00% 10.34 End-of-day quote.-22.89%
THE PACIFIC SECURITIES CO., LTD -0.40% 2.52 End-of-day quote.-23.17%
TIMES CHINA HOLDINGS LIMITED -10.23% 0.79 Delayed Quote.-76.66%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.18% 7.09488 Delayed Quote.11.41%
WUHAN GUIDE INFRARED CO., LTD. 0.87% 11.62 End-of-day quote.-32.80%
All news about SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.
08/26Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the Half Year ..
CI
05/29Zero-COVID, big money: China's anti-virus spending boosts medical,..
RE
05/11Accuracy of Runda Medical’s COVID-19 Testing Questioned by Shanghai Bourse
MT
05/11Shanghai firm says affiliate carrying out checks after COVID test accuracy questioned
RE
04/27Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the First Quar..
CI
04/26Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the Full Year ..
CI
2021Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the Nine Month..
CI
2021Micro rock medicine announced that it has received CNY 100 million in funding from Shan..
CI
2021Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the Half Year ..
CI
2021Shanghai Runda Medical Technology Co., Ltd. Reports Earnings Results for the First Quar..
CI
More news
Financials
Sales 2022 10 444 M 1 468 M 1 468 M
Net income 2022 417 M 58,6 M 58,6 M
Net Debt 2022 - - -
P/E ratio 2022 14,4x
Yield 2022 2,22%
Capitalization 5 992 M 842 M 842 M
Capi. / Sales 2022 0,57x
Capi. / Sales 2023 0,46x
Nbr of Employees 3 200
Free-Float 51,5%
Chart SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.
Duration : Period :
Shanghai Runda Medical Technology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 10,34
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Hui Liu Vice Chairman & General Manager
Jing Zhi Xu Independent Director
Zheng Chen Director & Deputy General Manager
Zhen Ning Hu Director & Deputy General Manager
Qiu Quan Ding Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.-22.89%842
BIOMÉRIEUX-32.81%9 763
DIASORIN S.P.A.-29.62%6 182
LANTHEUS HOLDINGS, INC.158.57%5 135
NATERA, INC.-49.64%4 560
AUTOBIO DIAGNOSTICS CO., LTD.0.09%4 542